Last edition
News about Global Pharma
Neuraxpharm and Pharmathen to Co-Develop Long-Acting Injectable Therapies
Under this agreement, Neuraxpharm will have exclusive rights to commercialise these therapies in Europe, and in countries outside of Europe where the group has a direct presence, while Pharmathen will have exclusive rights for North America and all other countries not covered by Neuraxpharm.
Global Pharma | 23/12/2024 | By Aishwarya | 452
Valneva Signs Agreement with Serum Institute of India for its Single Shot Chikungunya Vaccine
The collaboration to support broader access to the vaccine in low-and-middle-income countries (LMICs) in the region falls within the framework of the USD 41.3 million funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 2024 with co-funding from the European Union.
Global Pharma | 23/12/2024 | By Manvi | 633
The aptamer, originally developed to treat osteogenesis imperfecta, has been granted Orphan Drug Designation and Pediatric Rare Disease Designation by the US Food and Drug Administration (FDA).
Global Pharma | 23/12/2024 | By Manvi | 274
Photys Therapeutics and with Novo Nordisk to Develop Induced Proximity PHICS Technology
Under the terms of the agreement, Photys is eligible to receive up to USD 186 million in upfront, development and commercial milestone payments, in addition to R&D funding and tiered royalty payments on commercial sales.
Global Pharma | 23/12/2024 | By Aishwarya | 595
CuraTeQ Biologics Secures UK MHRA Approval for Bevqolva
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins.
Global Pharma | 23/12/2024 | By Aishwarya | 661
Verismo Therapeutics Completes Merger to Accelerate Clinical Development
The merger will accelerate the clinical development of SynKIR™-110 and SynKIR™-310 for solid tumor and blood cancer patients, respectively, solidifying Verismo's and HLB Group's collective mission to advance its innovative KIR-CAR platform for patients worldwide.
Global Pharma | 21/12/2024 | By Aishwarya | 719
Vanda Pharmaceuticals Receives Orphan Drug Designation Granted for VGT-1849A
VGT-1849A is a novel ASO treatment candidate for PV and other JAK2-driven hematologic malignancies.
Global Pharma | 21/12/2024 | By Aishwarya | 938
LSPedia to Expand Globally with New Office Launch in India in January 2025
The Hyderabad office will play a key role in LSPedia's global growth strategy, delivering exceptional service to customers in Bahrain, Bangladesh, Singapore, Switzerland, UK, and the balance of the EU.
Global Pharma | 21/12/2024 | By Aishwarya | 462
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Depakote Sprinkle Capsules, 125 mg, of AbbVie Inc.
Global Pharma | 20/12/2024 | By Manvi | 250
Novo Holdings Completes Acquisition of Catalent
With the completion of the transaction, holders of Catalent common stock are entitled to receive USD 63.50 per share in cash, representing a premium of approximately 47.5 percent to the 60-day volume-weighted average price as of February 2, 2024.
Global Pharma | 20/12/2024 | By Aishwarya | 335
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy